Results 11 to 20 of about 174,873,894 (246)

The Emerging Role of the Cancerous Inhibitor of Protein Phosphatase 2A in Pulmonary Diseases [PDF]

Medicina
Promising protein targets are observed to play a role in multiple pathways across a variety of diseases, such as the regulation of immune responses, cell cycle, senescence, and DNA repair.
Hamza Hamza, Dinesh Nirmal, Stephanie Pappas, Ugochukwu Ebubechukwu, Sunydip Gill, Adam Al-Ajam, Michael Ohlmeyer, Patrick Geraghty   +7 more
doaj   +7 more sources

Emerging roles of the cancerous inhibitor of protein phosphatase 2A (CIP2A) in ovarian cancer [PDF]

Scientific Reports
Ovarian cancer (OvCa) is the sixth most common gynaecological cancer in the UK, accounting for over 200,000 deaths worldwide. Cancerous Inhibitor of Phosphatase 2 A (CIP2A) is an oncoprotein and an endogenous inhibitor of PP2A.
Alice Filipe, Sayeh Saravi, Denis Mustafov, Suzana Panfilov, Simran Banger, Seyedehnajmeh Mousavikivaj, Maria Braoudaki, Senthilkumar Kailasam, Yasser Riazalhosseini, Michelle A. Sahai, Fotios Drenos, Cristina Sisu, Emmanouil Karteris   +12 more
doaj   +7 more sources

Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome. [PDF]

PLoS ONE, 2013
Previously, we reported that cancerous inhibitor of protein phosphatase 2A (CIP2A) mediates the apoptotic effect of bortezomib in hepatocellular carcinoma (HCC).
Hui-Chuan Yu, Duen-Ren Hou, Chun-Yu Liu, Chen-Si Lin, Chung-Wai Shiau, Ann-Lii Cheng, Kuen-Feng Chen   +6 more
doaj   +6 more sources

ETS1 mediates MEK1/2-dependent overexpression of cancerous inhibitor of protein phosphatase 2A (CIP2A) in human cancer cells. [PDF]

PLoS ONE, 2011
EGFR-MEK-ERK signaling pathway has an established role in promoting malignant growth and disease progression in human cancers. Therefore identification of transcriptional targets mediating the oncogenic effects of the EGFR-MEK-ERK pathway would be highly
Anchit Khanna, Juha Okkeri, Turker Bilgen, Timo Tiirikka, Mauno Vihinen, Tapio Visakorpi, Jukka Westermarck   +6 more
doaj   +10 more sources

Ring Finger Protein 1, a Novel Ubiquitin E3 Ligase Targeting Cancerous Inhibitor of Protein Phosphatase 2A to Suppress Smoking‐Induced Lung Tumorigenesis [PDF]

MedComm
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein that promotes cancer cell proliferation, invasion, and drug resistance. In this study, CIP2A expression was found to be higher in lung cancer tissues compared to adjacent normal ...
In‐ho Jeong, Jae Kwang Yun, Jun‐O. Jin, Geun Dong Lee, Peter Chang‐Whan Lee   +4 more
doaj   +5 more sources

From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer [PDF]

Frontiers in Genetics, 2023
Cancerous inhibitor of protein phosphatase 2A (CIP2A), initially reported as a tumor-associated antigen (known as p90), is highly expressed in most solid and hematological tumors. The interaction of CIP2A/p90, protein phosphatase 2A (PP2A), and c-Myc can
Beibei Chen, Beibei Chen, Huihui Hu, Huihui Hu, Xiaobing Chen, Xiaobing Chen   +5 more
doaj   +4 more sources

Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells [PDF]

Haematologica, 2013
The multiple cellular targets affected by proteasome inhibition implicate a potential role for bortezomib, a first-in-class proteasome inhibitor, in enhancing antitumor activities in hematologic malignancies.
Chun-Yu Liu, Chung-Wai Shiau, Hsin-Yu Kuo, Hsiang-Po Huang, Ming-Huang Chen, Cheng-Hwai Tzeng, Kuen-Feng Chen   +6 more
doaj   +4 more sources

Cancerous inhibitor of protein phosphatase 2A enhances chemoresistance of gastric cancer cells to oxaliplatin. [PDF]

World J Gastrointest Oncol, 2023
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a newly discovered oncogene. It is an active cell proliferation regulatory factor that inhibits tumor apoptosis in gastric cancer (GC) cells. CIP2A is functionally related to chemoresistance in various types of tumors according to recent studies.
Zhao YX, Ma LB, Yang Z, Wang F, Wang HY, Dang JY.   +5 more
europepmc   +4 more sources

Fusicoccin-A Targets Cancerous Inhibitor of Protein Phosphatase 2A by Stabilizing a C-Terminal Interaction with 14-3-3. [PDF]

ACS Chem Biol, 2022
The cancerous inhibitor of protein phosphatase 2A (CIP2A) is an oncoprotein found overexpressed in many types of cancer. CIP2A has been shown to stabilize oncoproteins such as cMYC by shielding them from PP2A-mediated dephosphorylation. Here we report that the penultimate residue Ser904 in the C-terminus of CIP2A can be phosphorylated to create a ...
Brink HJ, van Senten JR, De Vries-van Leeuwen IJ, da Costa Pereira D, Piersma SR, Jimenez CR, Centorrino F, Ottmann C, Siderius M, Smit MJ, de Boer AH.   +10 more
europepmc   +9 more sources

Protein interactome of the Cancerous Inhibitor of protein phosphatase 2A (CIP2A) in Th17 cells. [PDF]

Curr Res Immunol, 2020
ABSTRACT Cancerous inhibitor of protein phosphatase 2A (CIP2A) is involved in immune response, cancer progression, and in Alzheimer’s disease. However, an understanding of the mechanistic basis of its function in this wide spectrum of physiological and pathological processes is limited due to its poorly characterized interaction ...
Khan MM, Välikangas T, Khan MH, Moulder R, Ullah U, Bhosale SD, Komsi E, Butt U, Qiao X, Westermarck J, Elo LL, Lahesmaa R.   +11 more
europepmc   +7 more sources